This Medicine requires a physician's prescription.

Generic Name: Atorvastatin Calcium

Brand Name: Lipitor®

Strength: 20mg

Form: Tablet

Manufacturer: Pfizer Pharmaceuticals, LLC.

Packed by: Pfizer Manufacturing Deutschland GmbH

Marketing Authorization Holder: PF OFG Philippines, Inc.

Classification: Dyslipidaemic Agents, HMG CoA Reductase Inhibitor

Indication/Uses: Adjunct to diet for the treatment of patients w/ elevated total cholesterol (total-C), LDL cholesterol (LDL-C), apolipoprotein B (apo B), & triglycerides (TG). Increase HDL cholesterol (HDL-C) in patients w/ primary hypercholesterolemia (heterozygous familial & nonfamilial hypercholesterolemia), combined (mixed) hyperlipidemia (Fredrickson types IIa & IIb), elevated serum TG levels (Fredrickson type IV), & for patients w/ dysbetalipoproteinemia (Fredrickson type III) who do not respond adequately to diet. Reduction of total-C & LDL-C in patients w/ homozygous familial hypercholesterolemia. Reduce the risk of fatal CHD & non-fatal MI, stroke, revascularization procedures & angina pectoris in patients w/o clinically evident CV disease, & w/ or w/o dyslipidemia, but w/ multiple risk factors for CHD (eg, smoking, HTN, diabetes, low HDL-C, or a family history of early CHD). Reduce the risk of non-fatal MI, fatal & non-fatal stroke, revascularization procedures, hospitalization for CHF, & angina in patients w/ clinically evident CHD. Adjunct to lifestyle changes (eg, proper diet & exercise) to halt the progression of atherosclerosis (total atheroma or plaque vol) in patients w/ CAD & other individuals who are at high risk for CV disease. Reduce the risk for CV disease in patients w/ diabetes w/ moderately decreased eGFR. Reduce the risk of major CV events including stroke in patients w/ clinically evident CHD & CKD not requiring dialysis. Reduce the rate of GFR decline & progression of CKD in patients w/ clinically evident CHD &/or diabetes w/ microalbuminuria. Adjunct to diet to reduce total-C, LDL-C & apo B levels in boys & post-menarchal girls 10-17 yr w/ heterozygous familial hypercholesterolemia.